Stonepine Capital Management
Latest statistics and disclosures from Stonepine Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are EOLS, VSTM, ADMA, TENX, NKTR, and represent 32.30% of Stonepine Capital Management's stock portfolio.
- Added to shares of these 10 stocks: RARE (+$7.5M), INSM (+$5.6M), Eloxx Pharmaceuticals (+$5.5M), MDT, INDV, ABT, BSX, BMRN, EDSA, MSLE.
- Started 24 new stock positions in ORKA, MLTX, SENS, CALC, Eloxx Pharmaceuticals, HUMA, QTI, AZTR, BCAB, INSM. EPRX, SPRB, BMRN, BSX, RARE, ANL, NGEN, SINT, INDV, ABT, MDT, CLRB, NVCT, RNTX.
- Reduced shares in these 10 stocks: , TERN (-$5.3M), TENX, ADMA, ESTA, ZVRA, ARE, ACAD, XOMA, ABEO.
- Sold out of its positions in ACAD, ARE, Bioatla, CADL, ELDN, JANX, OABI, XBI, SRZN, TERN. VRCA, XOMA, ESTA.
- Stonepine Capital Management was a net seller of stock by $-84M.
- Stonepine Capital Management has $175M in assets under management (AUM), dropping by -30.07%.
- Central Index Key (CIK): 0001440771
Tip: Access up to 7 years of quarterly data
Positions held by Stonepine Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Stonepine Capital Management
Stonepine Capital Management holds 83 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Evolus (EOLS) | 8.0 | $14M | -7% | 2.0M | 6.94 |
|
| Verastem Com New (VSTM) | 7.3 | $13M | 3.3M | 3.82 |
|
|
| Adma Biologics (ADMA) | 6.7 | $12M | -26% | 1.4M | 8.37 |
|
| Tenax Therapeutics Com New (TENX) | 5.5 | $9.6M | -32% | 660k | 14.55 |
|
| Nektar Therapeutics Com New (NKTR) | 4.8 | $8.4M | +41% | 121k | 69.81 |
|
| Ultragenyx Pharmaceutical (RARE) | 4.3 | $7.5M | NEW | 225k | 33.39 |
|
| Camp4 Therapeutics Corp Com 13469v Ab 4 Camtek Ltd Note 12/0 (CAMP) | 3.5 | $6.1M | 1.4M | 4.37 |
|
|
| Insmed Com Par $.01 Call Option (INSM) | 3.2 | $5.6M | NEW | 40k | 140.00 |
|
| Eloxx Pharmaceuticals Com New | 3.2 | $5.5M | NEW | 397k | 13.88 |
|
| Kazia Therapeutics Sponsored Ads (KZIA) | 2.8 | $4.9M | 345k | 14.08 |
|
|
| Medtronic SHS Call Option (MDT) | 2.5 | $4.4M | NEW | 50k | 87.50 |
|
| Indivior Pharmaceuticals (INDV) | 2.3 | $4.1M | NEW | 100k | 41.03 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 2.3 | $4.0M | +10% | 425k | 9.38 |
|
| Abbott Laboratories Call Option (ABT) | 2.2 | $3.8M | NEW | 40k | 95.00 |
|
| Satellos Bioscience (MSLE) | 2.1 | $3.7M | +391% | 492k | 7.57 |
|
| Zevra Therapeutics Com New (ZVRA) | 2.1 | $3.7M | -46% | 259k | 14.34 |
|
| Abeona Therapeutics Com New (ABEO) | 2.0 | $3.4M | -34% | 557k | 6.18 |
|
| Boston Scientific Corporation Call Option (BSX) | 1.9 | $3.3M | NEW | 50k | 65.00 |
|
| Edesa Biotech Com New (EDSA) | 1.8 | $3.2M | +1421% | 456k | 6.99 |
|
| BioMarin Pharmaceutical Call Option (BMRN) | 1.8 | $3.1M | NEW | 50k | 62.50 |
|
| Cabaletta Bio (CABA) | 1.6 | $2.9M | +1734% | 917k | 3.11 |
|
| An2 Therapeutics (ANTX) | 1.5 | $2.7M | -22% | 552k | 4.84 |
|
| Xilio Therapeutics (XLO) | 1.2 | $2.2M | +252% | 226k | 9.58 |
|
| Adicet Bio Com New (ACET) | 1.2 | $2.1M | +10% | 246k | 8.64 |
|
| Xeris Pharmaceuticals Call Option (XERS) | 1.2 | $2.1M | -12% | 280k | 7.50 |
|
| Tela Bio (TELA) | 1.1 | $2.0M | 2.7M | 0.75 |
|
|
| Aytu Biopharma (AYTU) | 1.1 | $2.0M | +15% | 913k | 2.15 |
|
| Curis (CRIS) | 1.0 | $1.7M | -11% | 3.3M | 0.52 |
|
| Spruce Biosciences Com New (SPRB) | 0.9 | $1.6M | NEW | 29k | 54.00 |
|
| Si-bone Call Option (SIBN) | 0.9 | $1.5M | -13% | 100k | 15.00 |
|
| Okyo Pharma Shs New (OKYO) | 0.7 | $1.3M | 863k | 1.50 |
|
|
| Neumora Therapeutics Call Option (NMRA) | 0.7 | $1.3M | -16% | 500k | 2.50 |
|
| Pasithea Therapeutics Corp Com New (KTTA) | 0.6 | $1.1M | +164% | 2.2M | 0.52 |
|
| Sol-gel Technologies Shs New (SLGL) | 0.6 | $1.1M | -47% | 15k | 74.14 |
|
| Pulmonx Corp (LUNG) | 0.6 | $1.1M | +6% | 815k | 1.30 |
|
| X4 Pharmaceuticals Com New (XFOR) | 0.6 | $1.1M | -32% | 225k | 4.67 |
|
| Ardelyx Call Option (ARDX) | 0.6 | $1.1M | 150k | 7.00 |
|
|
| Delcath Sys Com New Call Option (DCTH) | 0.6 | $1.0M | 100k | 10.00 |
|
|
| In8bio Com New (INAB) | 0.6 | $980k | +4% | 695k | 1.41 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 0.6 | $974k | NEW | 50k | 19.47 |
|
| Quoin Pharmaceuticals Sponsored Ads (QNRX) | 0.6 | $966k | +273% | 200k | 4.84 |
|
| Maxcyte (MXCT) | 0.5 | $925k | -25% | 752k | 1.23 |
|
| Phathom Pharmaceuticals (PHAT) | 0.5 | $922k | +69% | 85k | 10.85 |
|
| Azitra Com New (AZTR) | 0.5 | $887k | NEW | 5.3M | 0.17 |
|
| Connect Biopharma Hldgs SHS (CNTB) | 0.5 | $867k | +17% | 364k | 2.38 |
|
| Cybin Com New (HELP) | 0.5 | $855k | -3% | 129k | 6.61 |
|
| Inhibikase Therapeutics Com New (IKT) | 0.5 | $804k | -58% | 396k | 2.03 |
|
| Zentalis Pharmaceuticals (ZNTL) | 0.4 | $784k | -39% | 162k | 4.85 |
|
| Cytomx Therapeutics (CTMX) | 0.4 | $769k | -48% | 205k | 3.75 |
|
| Mannkind Corp Com New Call Option (MNKD) | 0.4 | $750k | -51% | 250k | 3.00 |
|
| Nuvectis Pharma (NVCT) | 0.4 | $736k | NEW | 40k | 18.39 |
|
| Crescent Biopharma (CBIO) | 0.4 | $720k | -52% | 40k | 18.00 |
|
| Pmv Pharmaceuticals (PMVP) | 0.4 | $718k | -24% | 536k | 1.34 |
|
| Oruka Therapeutics (ORKA) | 0.4 | $714k | NEW | 7.5k | 95.17 |
|
| Radiopharm Theranostics Sponsored Ads (RADX) | 0.4 | $668k | 51M | 0.01 |
|
|
| Heron Therapeutics (HRTX) | 0.4 | $636k | -37% | 1.5M | 0.43 |
|
| Onkure Therapeutics Com Cl A (OKUR) | 0.3 | $596k | 131k | 4.56 |
|
|
| Nervgen Pharma Ord (NGEN) | 0.3 | $560k | NEW | 272k | 2.06 |
|
| Calcimedica Com New (CALC) | 0.3 | $545k | NEW | 622k | 0.88 |
|
| Arvinas Ord (ARVN) | 0.3 | $499k | +118% | 60k | 8.31 |
|
| Bioage Labs (BIOA) | 0.3 | $490k | -60% | 20k | 24.51 |
|
| Ocuphire Pharma (IRD) | 0.2 | $414k | +46% | 101k | 4.11 |
|
| Qt Imaging Hldgs (QTI) | 0.2 | $407k | NEW | 100k | 4.07 |
|
| Boundless Bio (BOLD) | 0.2 | $387k | -74% | 155k | 2.50 |
|
| Sintx Technologies Com New (SINT) | 0.2 | $333k | NEW | 209k | 1.59 |
|
| Cellectar Biosciences Com New (CLRB) | 0.2 | $291k | NEW | 105k | 2.78 |
|
| Eupraxia Pharmaceuticals Com 298736 Al 3 Euronet Worldwide Inc Note 0.750% 3/1 (EPRX) | 0.2 | $288k | NEW | 44k | 6.61 |
|
| Sab Biotherapeutics Com New (SABS) | 0.2 | $286k | +46% | 73k | 3.90 |
|
| Adlai Nortye Sponsored Ads (ANL) | 0.2 | $279k | NEW | 24k | 11.50 |
|
| Senseonics Hldgs (SENS) | 0.2 | $277k | NEW | 49k | 5.68 |
|
| Pliant Therapeutics (PLRX) | 0.2 | $263k | +2% | 231k | 1.14 |
|
| Codexis (CDXS) | 0.1 | $248k | -73% | 110k | 2.26 |
|
| Precision Optics Corp Inc Ma Com New (POCI) | 0.1 | $237k | -53% | 46k | 5.10 |
|
| Upstream Bio (UPB) | 0.1 | $231k | -4% | 33k | 6.92 |
|
| Rein Therapeutics Com New (RNTX) | 0.1 | $227k | NEW | 218k | 1.04 |
|
| CNS Pharmaceuticals (CNSP) | 0.1 | $199k | -31% | 42k | 4.78 |
|
| Humacyte (HUMA) | 0.1 | $181k | NEW | 231k | 0.78 |
|
| Kalaris Therapeutics (KLRS) | 0.1 | $123k | +47% | 30k | 4.07 |
|
| Processa Pharmaceuticals Com Shs (PCSA) | 0.1 | $106k | 55k | 1.92 |
|
|
| Bioatla Com New (BCAB) | 0.0 | $68k | NEW | 16k | 4.14 |
|
| Compugen Ord (CGEN) | 0.0 | $67k | -69% | 31k | 2.14 |
|
| Ovid Therapeutics (OVID) | 0.0 | $57k | -46% | 21k | 2.69 |
|
| Evaxion As Sponsored Ads (EVAX) | 0.0 | $54k | -10% | 18k | 3.10 |
|
Past Filings by Stonepine Capital Management
SEC 13F filings are viewable for Stonepine Capital Management going back to 2015
- Stonepine Capital Management 2026 Q2 restated filed Aug. 17, 2026
- Stonepine Capital Management 2026 Q2 filed Aug. 14, 2026
- Stonepine Capital Management 2026 Q1 filed May 14, 2026
- Stonepine Capital Management 2025 Q4 filed Feb. 13, 2026
- Stonepine Capital Management 2025 Q3 filed Nov. 13, 2025
- Stonepine Capital Management 2025 Q2 filed Aug. 13, 2025
- Stonepine Capital Management 2025 Q1 filed May 14, 2025
- Stonepine Capital Management 2024 Q4 filed Feb. 14, 2025
- Stonepine Capital Management 2024 Q3 filed Nov. 13, 2024
- Stonepine Capital Management 2024 Q2 restated filed Aug. 21, 2024
- Stonepine Capital Management 2024 Q2 filed Aug. 13, 2024
- Stonepine Capital Management 2024 Q1 filed May 15, 2024
- Stonepine Capital Management 2023 Q4 filed Feb. 13, 2024
- Stonepine Capital Management 2023 Q3 filed Nov. 13, 2023
- Stonepine Capital Management 2023 Q2 amended filed Aug. 16, 2023
- Stonepine Capital Management 2023 Q2 filed Aug. 11, 2023